[A20-91] Bempedoic acid/ezetimibe (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2021
Project no.:
A20-91
Commission:
Commission awarded on 30.10.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia
Added benefit not proven in either of both research questions (drug and dietary lipid-lowering options not exhausted/exhausted except for evolocumab)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relvant page of the G-BA website.